Gavin K. Reynolds

Gavin K. Reynolds

Auto-generated profile, based on publicly available information

Gavin K. Reynolds

Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2014 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
MLMichael Leane
Michael Leane
KPKendal Pitt
Kendal Pitt
GRGavin Reynolds
Gavin Reynolds
TGThe Manufacturing Classification System (MCS) Working Group
The Manufacturing Classification System (MCS) Working Group
This paper proposes the development of a drug product Manufacturing Classification System (MCS) based on processing route. It summarizes conclusions from a dedicated APS conference and subsequent discussion within APS focus groups and the MCS working party. The MCS is intended as a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the API and the needs of the formulation. It has many applications in pharmaceutical development, in particular, it will provide a common understanding of risk by defining what the "right particles" are, enable the selection of the best process, and aid subsequent transfer to manufacturing. The ultimate aim is one of prediction of product developability and processability based upon previous experience. This paper is intended to stimulate contribution from a broad range of stakeholders to develop the MCS concept further and apply it to practice. In particular, opinions are sought on what API properties are important when selecting or modifying materials to enable an efficient and robust pharmaceutical manufacturing process. Feedback can be given by replying to our dedicated e-mail address (mcs@apsgb.org); completing the survey on our LinkedIn site; or by attending one of our planned conference roundtable sessions.

1 May 2015 in Powder Technology
Verified
Journal Article
Closed access
TSTim Chan Seem
Tim Chan Seem
NRNeil A. Rowson
Neil A. Rowson
AIAndy Ingram
Andy Ingram
ZHZhenyu Huang
Zhenyu Huang
SYShen Yu
Shen Yu
GRGavin K. Reynolds
Gavin K. Reynolds

1 July 2005 in Chemical Engineering Science
Verified
Journal Article
Closed access
GRG.K. Reynolds
G.K. Reynolds
JFJ.S. Fu
J.S. Fu
YCY.S. Cheong
Y.S. Cheong
MHM.J. Hounslow
M.J. Hounslow
ASA.D. Salman
A.D. Salman

1 July 2010 in Computers & Chemical Engineering
Verified
Journal Article
Closed access
GRGavin Reynolds
Gavin Reynolds
RIRohit Ingale
Rohit Ingale
RRRon Roberts
Ron Roberts
SKSanjeev Kothari
Sanjeev Kothari
BGBindhu Gururajan
Bindhu Gururajan

13 November 2018 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
MLMichael Leane
Michael Leane
KPKendal Pitt
Kendal Pitt
GRGavin K. Reynolds
Gavin K. Reynolds
NDNeil Dawson
Neil Dawson
IZIris Ziegler
Iris Ziegler
TSThe Manufacturing Classification Sy
The Manufacturing Classification Sy
Following the first Manufacturing Classification System (MCS) paper, the team conducted surveys to establish which active pharmaceutical ingredient (API) properties were important when selecting or modifying materials to enable an efficient and robust pharmaceutical manufacturing process. The most commonly identified factors were (1) API particle size: small particle sizes are known to increase risk of processing issues; (2) Drug loading in the formulation: high drug loadings allow less opportunity to mitigate poor API properties through the use of excipients. The next step was to establish linkages with process decisions by identifying publicly-available proxies for these important parameters: dose (in place of drug loading) and BCS class (in place of particle size). Poorly-soluble API were seen as more likely to have controlled (smaller) particle size than more highly soluble API. Analysis of 435 regulatory filings revealed that higher doses and more poorly-soluble API was associated with more complex processing routes. Replacing the proxy factors with the original parameters should give the opportunity to demonstrate stronger trends. This assumption was tested by accessing a dataset relating to commercial tablet products. This showed that, for dry processes, a larger particle size was associated with higher achievable drug loading as determined by percolation threshold.

1 September 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
IGIan P. Gabbott
Ian P. Gabbott
FHFarhan Al Husban
Farhan Al Husban
GRGavin K. Reynolds
Gavin K. Reynolds